<DOC>
	<DOCNO>NCT02581839</DOCNO>
	<brief_summary>Subjects ask take part clinical research study test Eribulin , new drug . Eribulin investigational ( experimental ) anti-cancer agent approve Food Drug Administration ( FDA ) use patient brain metastasis . Eribulin FDA approve use patient metastatic breast cancer effect may may brain metastasis study .</brief_summary>
	<brief_title>Treatment Brain Metastases From Breast Cancer With Eribulin Mesylate</brief_title>
	<detailed_description>Primary Objectives : To determine 3-month central nervous system ( CNS ) -progression free survival ( PFS ) patient metastatic breast cancer brain metastasis treat eribulin mesylate . Secondary Objective ( ) : 1 . Estimate CNS complete partial response rate ( CR PR ) duration CNS response patient population . 2 Evaluate toxicity patient breast cancer brain metastasis treat eribulin mesylate . 3 Estimate clinical benefit rate ( CBR ) 3 month breast cancer patient brain metastasis treat eribulin mesylate . ( CBR sum CR , PR stable disease 3 month ) . 4 To estimate systemic disease ( extra cranial ) response rate duration systemic response patient population . 5 Overall survival patient population .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Female histologically confirm breast cancer . Patients must evidence metastatic disease ( non measurable disease eligible ) . Radiologically confirm metastatic brain lesion MRI . Brain metastasis breast cancer without prior WBRT , STS surgical resection . Progression must document least one lesion untreated SRS site surgery WBRT . Patients must neurologically stable stable dose steroid anticonvulsant least 1 week prior obtain baseline MRI brain , and/or least 1 week prior begin study treatment . No presence uncontrolled systemic disease tumor related complication , opinion investigator , might restrict life expectancy le 3 month . Patients may cytotoxic chemotherapy hormonal treatment breast cancer protocol treatment . Trastuzumab allow HER2 positive patient ) . Able comprehend willing sign Informed Consent Form ( ICF ) Karnofsky performance status ≥ 60 No brain radiation therapy &gt; 4 week No chemotherapy &gt; 3 week plan start protocol treatment Adequate bone marrow , renal , hepatic function , per local reference laboratory range follow : Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL Calculated creatinine clearance ( CrCl ) ≥ 30mL/min ( CockcroftGault method ) Patients normal , mild moderate hepatic dysfunction eligible . Calcium &lt; 10.1 mg/dL ( correct serum albumin follow : Corrected Calcium = ( 0.8 x ( 4 patient albumin ) ) + serum Ca Females childbearing potential must negative pregnancy test screen agree take appropriate precaution avoid pregnancy ( double barrier method birth control abstinence ) screen 3 month last dose treatment Able undergo MRI evaluation gadolinium contrast Patients presence active infection , abscess fistula Known leptomeningeal disease CNS midline shift . Any evidence severe uncontrolled systemic disease clinically significant cardiovascular , pulmonary , hepatic , renal metabolic disease . Severe conduction abnormality include significant QTc prolongation &gt; 450ms . Patients grade 3/4 peripheral neuropathy . Patients pacemaker ICD device . Previous treatment eribulin mesylate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>eribulin</keyword>
	<keyword>central nervous system</keyword>
	<keyword>CNS</keyword>
	<keyword>Eribulin Mesylate</keyword>
	<keyword>Halaven</keyword>
</DOC>